San Diego, February 1, 2023 /PRNewswire/ — The CLL Society made significant strides last year in providing critical information and support to patients with chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Together, we will advocate for all immunocompromised people and ensure that life-saving COVID-19 treatments are readily available. available to those who need them most. The nonprofit has also launched groundbreaking programs to support underfunded research aimed at resolving the complications of CLL/SLL, advancing care and treatment, and finding cures.
“Thanks to our dedicated supporters, last year we were able to take a monumental step forward, improving the lives of people with CLL/SLL today and creating a more hopeful future. We were able to provide it,” he said. carly booth, Executive Director of the CLL Society. “This progress makes 2023 even stronger and off to a great start.”
There have been many advances in CLL/SLL treatment over the past decade, but much research remains, so Boos said the CLL Association’s expansion of its research efforts comes at a critical time. . There are an estimated 200,000 people in the United States with CLL or SLL, a slow-growing blood cancer, with about 20,000 new cases diagnosed each year.
of January 2022, the CLL Society launched the Young Investigator Award Program. every year, $150,000 Grants are awarded to junior faculty members and/or postdoctoral researchers who have the potential to become future leaders in solving unmet disease needs.Doctor Christine RyanSenior Hematology/Oncology Fellow, Specializing in CLL/SLL and Lymphoma, Dana-Farber Cancer Institute bostonreceived the Young Researcher Award for the first time in January last year.
“We are proud to offer substantial support to these bold scientists who represent a new generation of leaders in advancing care and treatment. Brian Coffman, Physician, CLL Patient and Co-Founder, Executive Vice President and Chief Medical Officer of the CLL Society. “I would like to thank the Research Review Board for overseeing the rigorous selection process of the Young Investigator Award Program.”
Coffman said the CLL Society has also played a key role in advocating for immunocompromised individuals over the past year as the pandemic progressed and large sections of society have moved away from wearing masks and other protections. Koffman and his team are working with the NIH, CDC, and FDA to broaden the definition of who is immunocompromised and to increase the number of patients with hematologic cancers and those with CLL/SLL regardless of treatment status. You have successfully asked to include everyone. “We advocate for cancer patients in Congress and across institutions and encourage government health officials to consider the needs of those most vulnerable to COVID-19 when making decisions about testing and treatment. The CLL Association has also developed this effort into the International COVID-19 Blood Cancer Coalition (ICBCC). “We know the pandemic is not over, and our education and advocacy are key.”
In addition, the CLL Society has expanded virtual support groups for people with CLL/SLL or those caring for them. We now have 41 support groups with over 3,000 members, a 32% increase over 2021. These groups provide learning opportunities, patient-friendly physician-reviewed information, and opportunities to discuss concerns and concerns. Also in 2022, the CLL Society has enhanced its outreach through its Ask the Experts program, webinars, Facebook live educational events, and topic-specific support groups. Interest in these events has grown, attracting thousands of attendees throughout the year. The organization launched an improved website last spring, making the site easier to find and adding more important information for newly diagnosed people.
To ensure the CLL/SLL community remains armed with the latest information, the CLL Society is preparing to host a webinar called “ASH 2022 Comes to You.” December new orleansCoffman and other experts discuss potential implications for future treatment options. Topics include information on the role of combination therapy, a comparison of existing Her BTK inhibitors, new options for treating dual refractory disease, and Richter’s syndrome, a rare complication of CLL/SLL.The webinar will be held at 3:00 p.m. Eastern Standard Time upon February 9you can register for free at https://cllsociety.org/ash-2022-comes-to-you/.
Boos said the CLL Society has made significant strides toward achieving its five-year plan goals, including expanding coverage and providing funding for research. “This is all thanks to the wealth of support from our large and small donors, including our Board of Directors, Medical Advisory Board, Specialist Council, Patient Advisory Board, Industry Advisory Board, Patient Volunteers, and our incredible team. It was made possible by the wealth of support from and our staff,” she says. “We would like to thank everyone who helped move our mission forward in 2022, and we are well on our way to helping even more people in the CLL/SLL community in 2023 and beyond.”
About the CLL Association
The CLL Society is the leading authority for patients, families, caregivers, and health care professionals with chronic lymphocytic leukemia. Founded in 2013 by Dr. Brian Coffmanphysicians, CLL patients and advocates, and Patricia Coffman, a caregiver and advocate nonprofit organization, addresses the unmet needs of the chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) communities through patient education, advocacy, advocacy, and research. increase. The CLL Society is a registered 501(c)(3) tax-exempt organization. For more information, please visit https://cllsociety.org/.
Media contact:
Rachel Shakin
Mekky Media Relations
847-331-5861
353008@email4pr.com
View original content to download multimedia: -2022-starts-new-year-poised-for-further-growth-301735531.html
Source CLL Association
